EBMT 2024 | Exploring first-line CAR-T therapy for the treatment of DLBCL
Wendy Osborne, MBBS (Hons), MRCP, FRCPath, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, explores the potential expansion of CAR-T therapies into first-line treatment for diffuse large B-cell lymphoma (DLBCL). While currently used for patients relapsing within 12 months of first-line treatment, Dr Osborne highlights the possibility of CAR-T moving to first-line therapy or treating those with later relapses. Data from the ALYCANTE trial (NCT04531046) also supports CAR-T therapy for patients unfit for autologous stem cell transplantation (autoSCT). This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
